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The terms used to describe different states of myocardial health and disease are poorly defined. Imprecision and inconsistency in nomenclature
can lead to difficulty in interpreting and applying trial outcomes to clinical practice. In particular, the terms ‘viable’ and ‘hibernating’ are com-
monly applied interchangeably and incorrectly to myocardium that exhibits chronic contractile dysfunction in patients with ischaemic heart
disease. The range of inherent differences amongst imaging modalities used to define myocardial health and disease add further challenges
to consistent definitions. The results of several large trials have led to renewed discussion about the classification of dysfunctional myocardial
segments. This article aims to describe the diverse myocardial pathologies that may affect the myocardium in ischaemic heart disease and car-
diomyopathy, and how they may be assessed with non-invasive imaging techniques in order to provide a taxonomy of myocardial dysfunction.
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Introduction
Studies have demonstrated the benefits of pharmacological1 –8 and
device interventions9 for patients with left ventricular systolic dys-
function (LVSD) of ischaemic origin. While there are clear
theoretical benefits in improving blood supply to large areas of
dysfunctional ‘viable’ myocardium, several recent clinical trials
have failed to demonstrate improved outcomes following
revascularization.10–12
One explanation for these results may be the terminology
employed to describe myocardial health. In particular the terms
‘viable’ and ‘hibernating’ are often used interchangeably and some-
times incorrectly. ‘Viable’ is a summative term used to describe a
range of myocardial states including both normal and diseased seg-
ments that nonetheless contain a substantial number of cardiac
myocytes. Viable myocardial segments can thus include partial
thickness scar with fairly normal cardiac myocyte function in the
residual portion or myocytes that exhibit contractile dysfunction
or failure. On the other hand, ‘hibernating’ myocardium refers
only to the latter subgroup and can be narrowly defined as
chronically dysfunctional, ischaemic myocardium that recovers
contractile function following improvement in myocardial perfu-
sion limitation. It follows that assessment of ‘viability’ can be
made, to a large degree, prior to revascularization, but identifica-
tion of ‘hibernation’ may only be retrospective. Furthermore,
identifying myocardium as ‘viable’ does not necessarily imply
‘hibernation’ or functional recovery following revascularization, as
is sometimes assumed.
A second challenge in the taxonomy of myocardial dysfunction is
that it may be assessed with a range of non-invasive imaging techni-
ques. The available techniques differ fundamentally in method-
ology, the properties of acquired images and the tests’ limitations.
Therefore, discrepancies between the modalities are inevitable,
making consistency in the definition of myocardial states across im-
aging fields challenging. Understanding these differences is impera-
tive, especially in the design and interpretation of studies to
determine the role of revascularization in patients with long-
standing LVSD.
This article creates a clinical taxonomy for the different states of
myocardium that may exist and coexist in ischaemic heart disease
and cardiomyopathy with reference to histology and non-invasive
imaging techniques.
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Available imaging techniques
Non-invasive imaging techniques assess different aspects of myocar-
dial health: function and morphology, perfusion, metabolism, and
tissue characterization (Table 1).
Function and morphology
Echocardiography provides real-time cine assessment of cardiac
structure, myocardial wall thickness, and contractile function. Tissue
Doppler imaging (TDI) adds quantification of myocardial motion
and global longitudinal strain can be used to detect subtle systolic
and diastolic abnormalities that may have greater prognostic value
compared with LVEF.13,14 Cardiac magnetic resonance (CMR) pro-
duces high-resolution morphological and cine images of the heart in
unrestricted imaging planes and with high accuracy and reproducibil-
ity.15,16 In addition, cine CMR with tissue tagging or feature tracking
analysis allows quantitative assessment of segmental contractile
function. Both echocardiography and CMR can be combined with
pharmacological (dobutamine) or physiological (treadmill/static
bike) stress to detect ischaemia and viable, dysfunctional myocar-
dium17,18 through demonstration of contractile reserve. Single pho-
ton emission computed tomography (SPECT) and positron
emission tomography (PET) can provide information on global
and regional contractile function, but at a lower resolution than
echocardiography and CMR. Nuclear techniques are less suited
than echocardiography and CMR to measure wall thickness. With
all imaging techniques, assessment of segmental contractile reserve
is significantly limited by adjacent wall motion abnormalities due to
‘tethering’.19
Perfusion
Myocardial contrast echocardiography is used to measure perfusion
by observing the distribution of intravascular microbubbles in the
myocardium and provides a surrogate of myocardial blood flow.20
Myocardial perfusion CMR tracks the myocardial passage of pre-
dominantly extracellular paramagnetic contrast agents21 and allows
estimation of absolute myocardial flow (MBF) and myocardial per-
fusion reserve (MPR).22 Single photon emission computed tomog-
raphy and PET detect perfusion defects through a reduction of
signal from radionucleotide bound perfusion tracers in the region
of interest23; PET is considered the ‘gold-standard’ for quantitation
of MBF and MPR (Figures 1–3).
Metabolism
The principal method for metabolic myocardial imaging is currently
PET, which allows myocardial metabolic substrate utilization to be
characterized and quantified. Magnetic resonance spectroscopy is
a less widely used method to interrogate myocardial energetics.
Tissue characterization
Non-invasive tissue characterization is predominantly performed
with CMR. Late gadolinium enhancement (LGE) CMR allows iden-
tification of scar and focal fibrosis. T1 and extracellular volume
(ECV) measurement appears a useful and reproducible surrogate
for diffuse myocardial fibrosis,24,25 while T2-weighted CMR pro-
vides assessment of myocardial oedema. Integrated back-scatter
echocardiography, which provides assessment of tissue fibrosis
might also be applied in this context.
Future directions
Hybrid systems that combine anatomical with perfusion or metabolic
imaging (e.g. PET/MR) are becoming available whilst molecular
imaging may soon allow identification of specific biological processes.
Taxonomy for myocardial
segments
(1) Normal
(2) Ischaemic
(i) Reversible ischaemia
(a) Acute prolonged ischaemia
(b) Chronic intermittent ischaemia
(ii) Stunning
(iii) Hibernation
(iv) Infarction
(3) Myopathic
Normal
Definition: Normal myocardium is by definition viable and metabol-
ically active with normal contractile function and exhibiting con-
tractile reserve in response to increased demand.
Metabolism:Normal cardiac function, including contraction, relax-
ation, and ionic regulation, is dependent upon adenosine triphos-
phate (ATP) metabolism. The majority of ATP consumption
occurs in myo-fibrils throughout the cardiac cycle. Further ATP is
used to regulate sarcolemmal calcium and, at the membrane,
Na+/K+ ATPase transporter.26,27 The heart consumes ATP rapidly
and is dependent upon constant renewal of ATP, which in turn is de-
pendent upon creatine phosphate levels. Were ATP production to
cease and consumption to continue unchecked, cardiac stores
would be depleted in 10–15 s.26 There are three main pathways
by which ATP is synthesised: fatty acid oxidation, ketone body, and
carbohydrate metabolism. Fatty acid oxidation yields the most ATP,
though all pathways share a common endpoint of mitochondrial
ATP synthesis.28 In situations of increased metabolic demands, the
proportion of ATP derived from carbohydrate metabolism in-
creases (Figure 4).27
Histology: More than 70% of left ventricle (LV) myocardial tissue
volume is cardiac myocytes; the rest is vasculature and extra cellular
matrix (ECM).29 Predominantly containing collagen types I and III,
ECM composition is regulated by a number of factors, including cir-
culating neuro-hormones and mechanical strain.30,31
Imaging, morphology, and function: The LV is a conical structure that
tapers from base to apex. The normal LV wall has a thickness of be-
tween 6 and 10 mm in men, and 6 and 9 mm in women,32 in diastole
and thickens uniformly by at least 50% in systole. In response to in-
creasing demand, contraction becomes increasingly dynamic.
As well as function, it is also possible to assess the constituents of
myocardium and tissue homogeneity. By CMR the signal in healthy
myocardium is uniform on T1 and T2 weighted and contrast en-
hanced images. Semi-quantitative assessment of the ratio of T2 sig-
nal in healthy heart to skeletal muscle is ,1.9.33 Quantitative
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Table 1 Summary of key imaging modalities, and aspects assessed in defining myocardial
Morphology and resting function Stress function/contractile reserve Perfusion Metabolism Tissue characterization
Echo
Strengths Readily assessed in a range of situations.
Widely accessible
Doppler, tissue Doppler, and GLS
provide additional important indices
Contrast improves accuracy*
Physiological or pharmacological
stressors may be employed
Crude visual assessment of scar,
Maybe quantified with integrated background
scatter (not in routine clinical practice)
Weaknesses Limited by habitus and lung disease
Greater inter-observer variation and less
reproducible than CMR**
Affected by tethering in the presence of
multiple wall motion abnormalities
Microbubble perfusion remains
predominantly a research tool
Potential lack of local expertise
Not assessed
CMR
Strengths Multiplanar imaging with excellent
reproducibility#
Myocardial mechanics may be assessed as
per tissue Doppler
Physiological or pharmacological
stressors may be employed
Highly reproducible
Visual assessment
Quantification of perfusion reserve
possible
Excellent spatial resolution
Focal scar identified with LGE
Quantification of fibrosis (T1 mapping) and
oedema (T2 mapping)
Weaknesses Less accessible than echo
Unsuitable in critical illness
Limited by presence of some implantable
cardiac devices & extreme obesity
Stress limitations similar to echo
Exercise stressless practical
Availability
Absolute quantification of perfusion
Standard perfusion not ‘whole
heart’ coverage
Gadolinium CI if eGFR , 30 mL/
min/1.73 m2
Not assessed in clinical routine
practice, MRS available in some
centres
SPECT
Strengths Assessment of systolic function possible
during gated perfusion examination
Whole heart coverage
Perfusion defect size may be
quantified
Weakness Other aspects of cardiac function not
assessed
Not assessed Quantitative assessment not
possible
Lower spatial resolution than PET
and CMR
Potential imitations in balanced
ischaemia‡‡‡
Ionising radiation
Not assessed Inferred only—scar over estimated‡‡
PET
Strengths Gold standard for perfusion
quantification
Excellent spatial resolution
Whole heart coverage
Non-invasive assessment of
carbohydrate and lipid
metabolism possible
Weaknesses Not usually assessed Not assessed Exposure to ionising radiation Exposure to ionising radiation Tissue composition inferred from
metabolism/perfusion findingsS
Symbols: *136, **137, #16,17, ‡‡139, ‡‡‡140, S66.
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measurement of the T1 signal, by T1 mapping, shows normal values
in narrowly defined ranges,34 but depend on scanner field strength
and pulse-sequence used.34Extracellular volume, calculated using
pre- and post-contrast T1 mapping, is less method dependent and
is 26+3% in healthy myocardium.24
Nuclear techniques of perfusion and metabolism display uniform
signal throughout the myocardium (Figure 5). Myocardial perfusion
may be quantified both at rest and hyperaemia, allowing calculation
of MPR. By PET normal resting MBF is 0.7 mL/min/g, increasing to
2.75 mL/min/g on stress, with a flow reserve of .4.35 ‘Gold-
standard’ PET flow quantification is not without limitation, especially
when the flow reduction is only mild.36 Estimates of absolute MBF
with CMR show limited agreement with PET,37 though MPR corre-
lates well with PET in health and disease,37 with normal MPR by
CMR being 2.2.38
Ischaemic
Reversible ischaemia
Definition: Myocardial ischaemia is a mismatch of oxygen supply and
demand that precipitates change from aerobic to anaerobic cellular
respiration.
Metabolism: Ischaemia may either be complete, due to coronary
occlusion, or limited due to epicardial coronary artery stenosis or
abnormalities of the myocardial microvascular circulation. The de-
gree of ischaemia is also determined by the presence and extent
Figure 2 Patterns of late gadolinium enhancement by CMR seen in different pathologies. (A) Sub-endocardial infero-lateral enhancement in
myocardial infarction. (B) Anterior mid wall enhancement in dilated cardiomyopathy. (C) Lateral epicardial and pericardial enhancement in
myo-pericarditis.
Figure 1 Intra-venous contrast agent use in echocardiography. Left, rest images have poorly defined endocardial border. Right, following ad-
ministration of intra-venous contrast agent the apical wall motion defect is evident. Taken from Plana et al.141
Figure 3 Radionuclide perfusion imaging: (A) Hyperaemic stress
single photon emission computed tomography and (B) positron
emission tomography imaging (B) of the same patient. (A) shows
an apparent inferior perfusion defect not present in (B) suggesting
single photon emission computed tomography attenuation
artefact.50
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of a collateral circulation that can develop in humans with estab-
lished coronary artery disease.
Changes in cell metabolism begin within one minute of onset of
severe ischaemia. Sub-endocardial tissue becomes ischaemic first
followed by sub-epicardial tissue.39 Shortly after the onset of severe
ischaemia, oxygen present in myocardium is consumed and normal
oxidative metabolism ceases. At the same time, electron transport
across cell membranes decreases and myocyte contraction be-
comes impaired. During this initial phase, anaerobic respiration re-
places aerobic respiration as the dominant source of ATP, and
glycogen replaces fatty acids and glucose as the substrate for energy
production.26 Anaerobic respiration in this setting provides ap-
proximately one-quarter of the amount of ATP as aerobic metabol-
ism. Due to adverse intra-cellular conditions, including falling pH,
ATP production at this rate is only sustained for 1 min before con-
tinuing at a much lower rate for up to 1 h.26
In non-severe ischaemia, a degree of aerobic respiration con-
tinues, consequently more ATP is produced compared with anaer-
obic glycolysis. Furthermore, hydrogen ions and lactate that
accumulate in severe ischaemia are produced less quickly, and
‘washed out’ of still perfused tissue, preserving a more physiological
environment.
Once ischaemia has resolved, recovery of normal function is vari-
able. Abnormalities of systolic function may persist for several days,
myocardium that fails to recover normal systolic function immedi-
ately is said to be ‘stunned’.40
Histology: Abnormal function of cell membrane channels leads to
myocyte oedema shortly after onset of ischaemia. In addition fol-
lowing short duration of severe ischaemia, depletion of glycogen
stores, and the presence of ‘I-bands’ in myo-fibrils are seen on elec-
tron microscopy.41
Imaging, morphology, and function
Figure 4 Normal myocyte metabolism: taken from Myocardial Substrate Metabolism in the Normal and Failing Heart.28
Figure 5 Normal single photon emission computed tomography examination: Left ventricle seen in short axis, vertical long axis, and horizontal
long axis. Adapted from Hasegawa et al.142
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Acute prolonged ischaemia
Shortly following the onset of ischaemia, regional systolic function
becomes impaired and may remain so for days after the ischaemic
insult.40 Echocardiography is most commonly used to identify wall
motion abnormalities associated with acute ischaemia. Single pho-
ton emission computed tomography and PET are rarely used clinic-
ally in the setting of acute ischaemia. On CMR, wall motion and
thickness are assessed in a similar fashion to echocardiography. In
addition, oedema is readily detectable and quantifiable as areas of
high signal on T2-weighted images.42 T1 and T2 mapping may pro-
vide similar, quantitative information. The oedematous zone may be
quantified to determine the extent of myocardial salvage following
intervention, and delineate the ‘area at risk’.
Chronic intermittent ischaemia
Exercise or dobutamine stress echocardiography allows detection
of ischaemia as well as determining its location and extent.43 Ischae-
mic myocardium shows reduced contractile reserve with regional
wall motion abnormalities developing at increasing levels of stress
(Figure 6).
Cardiac magnetic resonance also allows detection of ischaemia
through assessment of regional systolic function. Tissue perfusion
can be assessed using first pass adenosine stress CMR (Figure 7).
Quantitative assessment of perfusion with CMR has limited agree-
ment with PET imaging44 and is less commonly used in clinical prac-
tice than qualitative assessment.
Single photon emission computed tomography is commonly used
in the investigation of chronic intermittent ischaemia, and while im-
age quality on PET is superior to SPECT, availability of PET limits util-
ity. The sensitivity and specificity of SPECT compare well with other
non-invasive imaging techniques45; whole heart acquisition allows
accurate quantification of the extent of ischaemia, a measure that
may have prognostic value.46 Image interpretation may be limited
by attenuation artefact in the inferior wall and anterior wall, espe-
cially in women.47 In addition to perfusion imaging and LV function,
transient LV dilation (transient ischaemic dilation—TID) may be ap-
preciated on stress SPECT imaging, marking adverse prognosis.48
Transient ischaemic dilation may either represent true dilation as
a result of severe coronary disease and stunning, or rather may re-
flect sub-endocardial defects not appreciated on perfusion
imaging.49
In head-to-head studies, the theoretical advantages of PET over
SPECT have been demonstrated.36,50 As well as detection of ischae-
mia it is also possible to measure myocardial blood flow with PET,51
enabling quantitative assessment of myocardial blood flow reserve,
which correlates strongly with coronary artery stenosis severity.52
Stunning
Definition: Myocardium is ‘stunned’ when contractile function is de-
pressed following transient ischaemia, prior to a full recovery, and
having sustained no irreversible myocyte damage. The mechanism
of sustained systolic dysfunction in stunning is incompletely under-
stood. However, it is believed that oxygen free radical formation and
elevated myocardial calcium levels may lead to damage of myocar-
dial proteins or sarcoplasmic reticulum.53
Metabolism: Sub-epicardial and sub-endocardial myocardial blood
flow normalises quickly following restoration of normal coronary
flow, however normal myocardial metabolism takes time to re-
cover. Metabolic changes in transient ischaemia, including fall in
myocyte ATP, phosphocreatine and pH, take several hours to re-
verse.54 Post-ischaemic myocardial oxidative and glucose metabol-
ism remain depressed by 20% of normal levels for several hours
after an ischaemic insult, and take up to 1 week to recover to near
normal levels.55
Histology: Histological changes reflect sustained ischaemia. In
common with metabolic changes, resolving myocardial oedema,
myocardial glycogen, and ATP depletion40 may be detected several
days later.
Imaging, morphology, and function: Systolic function of affected seg-
ments is impaired in stunning. The speed of recovery of systolic
function is variable and may be related to the duration and severity
of the ischaemic insult,40,56,57 Abnormalities of diastolic function,
whether assessed by CMR, conventional or tissue Doppler persist
beyond systolic abnormalities.58,59 It is likely that stunning is an un-
der-appreciated phenomenon as functional abnormalities asso-
ciated with acute ischaemia will often have recovered.
Dobutamine stress echocardiography in reperfused acute MI has
been shown to predict recovery of dysfunctional segments with sen-
sitivity and specificity of 86 and 90%, respectively.60
Cardiac magnetic resonance demonstrates changes in keeping
with ischaemia including high signal on T2-weighted images indica-
tive of oedema, as well as regional systolic and diastolic wall motion
abnormalities.
Positron emission tomography FDG metabolism assessment
may demonstrate depressed levels of glucose metabolism, but
no significant metabolism perfusion mismatch, as in hibernation, is
seen.58
Hibernation
Definition: Chronically dysfunctional viable myocardium of ischaemic
origin that recovers systolic function following revascularization.
The processes underlying the development of hibernation remain
unclear, although several mechanisms have been proposed. It is
thought that although resting blood flow is normal, coronary flow
reserves are low.61 This leads to repeated episodes of ischaemia
and repetitive myocardial stunning, causing a complex series of
physiological and structural changes characteristic of hibernation.62
The abnormalities seen in hibernating myocardium become more
pronounced as the duration of hibernation increases.63,64 The
time course of recovery of LV systolic function following revascular-
ization is dependent upon the severity of myocardial change, with
some studies suggesting that irreversible remodelling may occur
with extended hibernation despite successful revascularization.64,65
However, it is not known if delayed recovery may occur beyond
study duration.66
Metabolism: There remains debate regarding the metabolic
changes present in hibernation. However, there is evidence to sug-
gest that glucose uptake and utilization are increased and fatty acid
metabolism is decreased in hibernating myocardium.67,68
Histology: Hibernating myocardium is macroscopically similar to
normal myocardium. However, at a microscopic level, there are dif-
fuse changes within the myocyte and extracellular ultrastructure.
All types of collagen increase in the ECM of hibernating segments,
and are more than twice that found in normal myocardium when
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de-differentiation is severe.62 Structural changes in the ECM be-
come more pronounced as duration of hibernation increases.64,69
Furthermore, there is down-regulation of myocyte mitochondria
and increased glycogen storage when compared with both normal
and remote myocardium.62,68 These changes reflect alteration of
mRNA expression and disorganization of cytoskeletal proteins as
a result of cellular de-differentiation.
Imaging, morphology, and function: On functional imaging, hiberna-
ting myocardium has impaired resting systolic function, and will typ-
ically be hypo- or akinetic. Diastolic wall thickness is .6 mm by
CMR70 or 7 mm on trans-thoracic echocardiography,65 though re-
cent studies have demonstrated that thinning below these thresh-
olds, in the absence of extensive scar, does not preclude
recovery.71 With inotropic stimulation, hibernating myocardium
shows ‘contractile reserve’ or a ‘biphasic response’, with an im-
provement in contractile function on low-dose/effort stress prior
to deteriorating at higher workloads.72 Low dose stress TDI allows
quantification of systolic function: Doppler tissue velocities in-
crease more in hibernating myocardium than in dysfunctional tissue
that does not show improvement in systolic function following re-
vascularization (Figure 8).73,74
Cardiac magnetic resonance examination allows for accurate as-
sessment of diastolic wall thickness and regional wall motion abnor-
malities. Late gadolinium enhancement CMR contributes only
indirectly to the diagnosis of hibernation. On LGE CMR, hibernating
myocardium has the same signal characteristics as normal
Figure 6 Schematic of wall motion abnormalities in ischaemia, hibernation, sub-endocardial, and infarction.
Figure 7 Imaging in chronic ischaemia: (A) cardiac magnetic resonance first pass perfusion demonstrating mid-ventricular anterior and septal
abnormality. (B) Single photon emission computed tomography demonstrating the anterior and septal stress (top row) abnormality that resolves
at rest. (C) Angiography in the same patient showing severe left anterior descending stenosis. Adapted from Greenwood et al. Cardiovascular
magnetic resonance and single photon emission computed tomography for diagnosis of coronary heart disease: a prospective trial.143
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myocardium, with signal uniformly nulled. Late gadolinium enhance-
ment CMR therefore only excludes the presence of myocardial infarc-
tion as the cause of contractile dysfunction, suggesting hibernation as
one of several potential causes. Absence of LGE in dysfunctional seg-
ments in ischaemic heart disease may predict functional recovery fol-
lowing revascularization (Figure 9).75 Cardiac magnetic resonance
prediction of recovery can be further enhanced by combined use of
functional, LGE, and dobutamine stress imaging. Hibernating myocar-
dium has reduced resting function, the absence of LGE and a biphasic
response to dobutamine stress.72 Finally, myocardial perfusion can be
assessed and quantified by first pass CMR. Resting MBF (mL/min/g)
is normal in hibernating myocardium, and hyperaemic blood flow is
reduced with subsequent improvement following successful
revascularization.76
In SPECT imaging cellular uptake of Thallium is dependent upon a
functional Na+/K+ ATPase and preserved sarcolemmal membrane
function.66 In hibernating myocardium, early acquisition following
tracer administration identifies a defect, reflecting impaired blood
flow on stress, though delayed early uptake may also be evident
on rest in severe LV dysfunction.77 On delayed acquisitions, the iso-
tope has been taken up by metabolically active myocytes in the hi-
bernating region, so the defect is reduced. Stress/redistribution
SPECT thus allows quantification of ischaemia and the extent of po-
tential recovery.78 Technetium-based tracers, which bind within
myocytes to mitochondria, identify viable myocardium similarly to
Thallium SPECT.
Positron emission tomography assessment is most commonly
based on the assessment of myocardial glucose uptake with FDG.
Tracer signal is proportional to metabolically active myocardium
and likelihood of recovery may be predicted by the glucose meta-
bolic rate (Figure 10).79,80,81 In addition, PET allows the detection
and quantification of MPR, which is reduced in hibernation.82,83
Hibernation with non-trans-mural scar
Hibernation commonly co-exists in the presence of sub-endocardial
infarction and as a consequence overlap of imaging findings may be
seen, e.g. sub-endocardial enhancement on LGE CMR, or both fixed
and inducible perfusion defects on nuclear study.
In the setting of partial infarction response to dobutamine stress on
functional imaging is reduced. Decreased circumferential strain mea-
sured by echocardiography further facilitates differentiation of normal
myocardium, sub-endocardial, and transmural infarction.84,85
The spatial resolution of CMR LGE enables the detection of small
volumes of infarction that may be missed by SPECT or PET. Trans-
mural extent of LGE predicts likelihood of systolic recovery: 60%
with 1–25% LGE, 42% with 26–50% LGE, and only 7% of segments
with .50% enhancement recovered at 3 months in a cohort with
predominantly chronic, mild LVSD (LVEF 43%).75 In a second mixed
cohort of acute and chronic patients with moderate LVSD (LVEF
38%) recovery rates were similar (0 LGE:73%, 1–25:56%, 26–
50:45%, .50%:5%).86
Where hibernation co-exists with acute abnormalities a ‘mixed
picture’ of imaging findings may result. Definitive classification of ab-
normalities in this setting is difficult and may require repeated im-
aging to classify myocardium.
Infarction
Definition: Myocardial infarction follows sustained ischaemia leading
to myocyte necrosis and subsequent remodelling and fibrosis.
Metabolism: Necrosis occurs when sustained severe ischaemia
leads to irreversible structural changes within the myocyte, includ-
ing mitochondrial swelling and disruption of the sacrolemma.41 In
the course of ischaemic injury, necrosis begins in the sub-
endocardiumwhere tissue perfusion is lowest and energy consump-
tion is highest, leading to ATP supply exhaustion and accumulation
of the by-products of glycolysis. Sub-endocardial infarction com-
mences 20 min after ischaemia onset. Prolonged ischaemia leads
to increasingly transmural necrosis, which moves as a ‘wave front’
from the endocardium to the epicardium,39 though sometimes
with sparing of a thin rim of sub-endocardium.
Histology: Characteristic histological changes occur during myo-
cardial infarction, and evolve until the infarcted region undergoes
scar replacement. On macroscopic examination there are few de-
tectable changes over the first 4 h. From 4 to 12 h myocardium be-
comes mottled. Over the next week, the infarct centre becomes
pale and yellows while developing red margins, followed by replace-
ment of necrotic infarct by fibrous scar tissue.87,88
Figure 8 Tissue Doppler in normal (A) and chronically ischaemic dysfunctional myocardium (B): E’ is related to the degree of interstitial fibrosis
adapted from Shan et al.144
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Microscopically, myocardium undergoes a series of changes re-
sponsible for the macroscopically appreciable abnormalities. During
the initial phase, glycogen depletion and oedema, in keeping with se-
vere ischaemia is seen on electron microscopy.89 Between 4 and
12 h, oedema, necrosis, and intra-myocardial haemorrhage are
seen. From 12 to 24 h neutrophil infiltration and ongoing necrosis
develop. This is followed within 24–48 h by the disappearance of
nuclei and striations, and macrophages remove dead cells at the
Figure 9 Increasing transmurality of late gadolinium enhancement predicts lack of response to revascularization in chronically ischaemic dys-
functional myocardium: Progressive transmurality of scar predicts lack of improvement in systolic function following revascularization. (A) 25% late
gadolinium enhancement of the inferior wall and infer-septum (B) 50% late gadolinium enhancement in the infero-lateral wall becoming increas-
ingly transmural inferiorly. (C) 100% late gadolinium enhancement of the inferior wall.
Figure 10 Perfusion-metabolism mismatching on PET in hibernating myocardium: (A) Short axis. (B) Vertical long axis. (C) Horizontal long axis.
Top row demonstrates a stress perfusion defect in the infero-lateral wall. Matched metabolism imaging shows preservation of metabolism in the
same territory indicating potential hibernation. Adapted from Bengel, Cardiac Positron Emission Tomography.50
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infarct border. Following this granulation tissue and collagen depos-
ition begins, eventually leading to the formation of collagen scar
(Figure 11).90,91
Imaging, morphology, and function: Wall motion abnormalities de-
velop before ECG changes or symptoms,92 while TDI systolic vel-
ocities decrease rapidly following onset of ischaemia.93 Following
transmural infarction, myocardium is akinetic and thins with time.
On stress or exercise there is no improvement in wall thickening
with the absence of contractile reserve.94 Sub-endocardial infarc-
tion results in wall motion abnormalities of varying severities, and
may be differentiated from transmural infarction using peak systolic
circumferential strain and strain rate on stress echocardiography.95
Cardiac magnetic resonance demonstrates gross anatomical
changes associated with infarction including remodelling, wall thin-
ning, and motion abnormalities.42 In addition, CMR imaging can be
used to delineate infarct extent, indicate the area at risk, and detect
microvascular and reperfusion injury.96,97 Late gadolinium enhance-
ment CMR after acute MI displays high signal in the infarcted area
due to persistence of gadolinium within areas of increased extracel-
lular volume and abnormal washout kinetics.42 In animal models, in-
farct enhancement with LGE CMR has been observed within 90 min
of the onset of ischaemia.98 In the acute phase, infarct extent may be
overestimated due to increased signal and contrast in the oedema-
tous peri-infarct zone.99 In acute myocardial infarction, LGE CMR
may show an area of low signal within the otherwise high-signal in-
farct zone. This reflects microvascular obstruction (MO) leading to
an absence of gadolinium delivery to the centre of the infarct. Exten-
sive MO is associated with no-flow on invasive coronary angiog-
raphy and adverse LV remodelling.100 Within an area of MO,
myocardial haemorrhage may occur, causing low signal on T2 and
T2* CMR.101 Haemorrhage represents more severe structural
change in the setting of acute MI and is also associated with adverse
LV remodelling following infarction.102 The combination of the in-
formation gained from T2 weighted, early gadolinium, and late gado-
linium images allows measurement of the area at risk, infarct size,
and myocardial salvage (difference between area at risk and infarct
size) (Figure 12).97
At the time of acute infarction SPECT imaging is not usually per-
formed. However in research settings, infarct area as delineated by
absent tracer uptake on SPECT correlates well with infarct size on
pathological specimens.103 In chronic infarction, metabolically active
myocytes are replaced by scar and the absence of an intact Na+/K+
ATPase leads to lack of uptake of the SPECT tracer within the region
of infarction. The limited spatial resolution of SPECT can lead to an
under-appreciation of the extent of infarction because small sub-
endocardial infarction may not be detected.104
In acute myocardial infarction, FDG PET allows detection of
infarction and the presence of viable tissue in or adjacent to the
infarcted territory. The absence of detectable glucose metabolism
is associated with irreversible myocardial injury.105 Myocardial
perfusion by PET in the acute MI zone is depressed, significantly
improves following coronary intervention, and may continue to
improve up to 2 weeks later.106
In the setting of chronic myocardial infarction, concordant reduc-
tion in signal from both perfusion and metabolism (NH3 and FDG
tracers, respectively) PET is seen and readily appreciated in trans-
mural infarction; however, in sub-endocardial infarction PET may
fail to detect small areas of sub-endocardial scar when compared
with CMR.107
Myopathic myocardium
Definition: Dysfunctional myocardium of non-ischaemic origin is con-
sidered to be myopathic. Myopathy covers a wide range of patholo-
gies. This review will focus on dilated cardiomyopathy, in which
pronounced isolated segmental systolic dysfunction is uncommon,
with only passing reference to other aetiologies.
Metabolism: Normal cardiac function relies upon matching of en-
ergy demand and consumption. This requires an appropriate oxygen
supply to myocytes, mitochondrial function, ATP transport to the
site of energy consumption, and a reliable feedback system to main-
tain appropriate metabolic rates. Energy depletion, perhaps due to
mitochondrial dysfunction, could be a primary reason for impaired
myocardial contraction. However, the primary defect may usually
be in the contractile apparatus or in calcium handling, which increase
metabolic demand. Importantly, myopathy may be an acquired phe-
nomenon in un-infarcted myocardium that has undergone remodel-
ling and may co-exist alongside segments affected by scar, ischaemia,
stunning or hibernation. In patients with mild heart failure secondary
Figure 11 Histological change following myocardial infarction: pathology of myocardial infarction, diagnostic histopathology 2013. (A) Light
microscopy of wavy mitochondrial fibres and interstitial oedema 4 h postmyocardial infarction. (B) Myocardial fibres 24 h post-myocardial infarc-
tion, myocardial thinning, and interstitial infiltration by polymorphonuclear leukocytes. (C) Granulation tissue 7–10 days post infarction. Near
complete removal of myocytes. (D) Light microscopy 2–3 weeks after infarction. Subendocardial fibrosis marked by arrowhead, with a small
area of myocardial fibre preservation between layers of collagen deposition. Adapted from Chang et al.145
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to idiopathic dilated cardiomyopathy any change myocardial sub-
strate utilization is subtle. In severe heart failure, cellular metabolism
changes substantially, with greater glucose and less free fatty acid
utilization,108,109 in most but not all studies.110
Histology: Histological abnormalities differ depending on the
underlying aetiology including myocyte disarray and interstitial fi-
brosis111 in hypertrophic cardiomyopathy (HCM) and fibro-fatty re-
placement in arrhythmogenic right ventricular cardiomyopathy. A
reduction of mitochondria in the failing heart is common.28 Differing
degrees of myocyte hypertrophy are seen depending upon the aeti-
ology of heart failure. However irrespective of aetiology, a common
finding is the expansion of the ECM and fibrosis due to local factors
and activation112 of the renin–aldosterone–angiotensin system.113
Collagen types I and III are the major structural components in the
cardiac ECM, providing both tensile strength and elasticity.114 In the
failing heart, collagen synthesis increases (especially type III colla-
gen), leading to accumulation of intercellular collagen, limiting ven-
tricular compliance, myocyte function, and contributing to both
systolic and diastolic dysfunction (Figure 13).115,116
Imaging, morphology, and function: Functional imaging by echocardi-
ography and CMR supplies important information for prognosis and
risk stratification including ejection fraction and left ventricular end
diastolic dimensions.117,118
Comprehensive structural assessment by echocardiography and
CMR may guide management and allow diagnosis of the underlying
cardiomyopathic process. For example, it is possible to differenti-
ate between morphologically similar cardiomyopathies on echo-
cardiography: Improvement in long-axis function on stress TDI
allows differentiation between ischaemic and non-ischaemic car-
diomyopathy.119 In the case of left ventricular hypertrophy, echo-
cardiographic 2D-strain assessment allows differentiation of HCM
and hypertensive LV hypertrophy, while TDI enables differenti-
ation of HCM and athlete’s heart.120,121
Tissue Doppler imaging of the mitral annulus and mitral inflow
velocity provides a non-invasive estimate of left atrial pressure.122
Cardiac magnetic resonance assessment of left atrial transit time
also correlates strongly with LV early diastolic pressure.123
Inmany cardiomyopathies, LGECMR shows characteristics patterns
of enhancement. The presence and extent of LGE predicts outcomes
in a range of cardiac diseases, including DCM,124 HCM,125 and ischae-
mic heart disease.126 Extracellular volume calculation allows measure-
ment of both diffuse fibrotic and infiltrative processes that are
unreliably assessed with visual analysis alone.127,128 T2*mapping allows
detection and tracking of iron overload cardiomyopathy.129
The ability of SPECT alone to differentiate ischaemic from DCM
is uncertain as mild stress perfusion defects are commonly seen with
Figure 12 Acute myocardial infarction on cardiac magnetic resonance: Top row: (A) High signal on T2-weighted image demonstrating Infero-
lateral oedema and ‘area at risk’. (B) Subendocardial infarction in the same patient on late gadolinium enhancement. Bottom row: (C) early gado-
linium enhancement image in a second patient with extensive lateral wall hypoenhancement. (D) Late gadolinium enhancement confirms infarction
and microvascular obstruction.
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both aetiologies.130,131 The defects seen have mild stress defect se-
verity ratios (.45%); however, similar abnormalities may be seen in
multi-vessel coronary disease precluding the use of SPECT as the
sole diagnostic tool in this situation.
Decreased free fatty acid metabolism with increased glucose me-
tabolism is found on PET examination in DCM.108 Hyperaemic
blood flow by PET is lower in DCM than in healthy controls,
2.23 mL/min/mL vs. 4.33 mL/min/mL in one report132 and perfusion
Figure 13 Histological abnormalities in cardiomyopathy: (A) Dilated cardiomyopathy, increased interstitial fibrosis at the blue arrow. (B)
Hypertrophic cardiomyopathy, increased interstitial fibrosis (blue), and myocyte disarray. (C) Fibro-fatty replacement in arrhythmogenic right ven-
tricular cardiomyopathy. Taken from Hughes, Asimaki and Saffitz, Gulati.146–148
Figure 14 Taxonomy of myocardial segments in left ventricular systolic dysfunction: This should be viewed as an aid to classification rather than
a decision tree. Function: thickness compared with ‘normal’ denotes resting state, with subsequent contractile reserve displayed with increase in
segmental thickness. Stunned myocardium may display increased thickness at rest due to oedema though may not be readily appreciable. Perfu-
sion: ‘horseshoe’ displays typical Single photon emission computed tomography/positron emission tomography finding whilst ‘donut’ displays car-
diac magnetic resonance findings: Single photon emission computed tomography/positron emission tomography: Red ¼ normal; pale
blue ¼ minimally decreased or normal; dark blue ¼ decreased. Cardiac magnetic resonance: grey ¼ normal; black¼hypoperfusion/ischaemia.
Oedema & Scar: ‘donut’ displays typical T2 weighted (blue) and late gadolinium enhancement findings (black is normal, shades of grey represent
late enhancement).
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abnormalities in DCM are progressively worse in more severe heart
failure133 and carry adverse prognosis.134
Clinical implications
Different imaging modalities assess different facets of myocardial
health and disease and are often complementary. An awareness of
the principles underlying acquisition, and the aspect of myocardial
health and pathology assessed is crucial.
The detection of ‘normal’ myocardium is straightforward, and can
be accomplished using any test capable of delivering good quality
anatomical images. The most appropriate method will vary depend-
ing upon patient and institute: In terms of practicality, availability, and
economy this will frequently be echocardiography. Atrial as well as
ventricular volumes and function should be carefully assessed to de-
tect more subtle disease. Minor deviations from normal, such as
small areas of infarction, may be undetected unless high-resolution
imaging methods such as LGE CMR are used.
Ischaemia detection or perfusion assessment may be performed
using either stress/exercise echo/CMR, CMR first pass perfusion or
nuclear imaging, and all are included in current practice guide-
lines.135 Single photon emission computed tomography is the most-
ly widely used modality worldwide, and PET remains the gold
standard. In some patients, it may be desirable to exclude valvular
disease or cardiomyopathy making DSE or CMR the most appropri-
ate choice of test.
Hibernation may only ever be identified retrospectively. How-
ever, in clinical practice the question most often posed relates to
the likelihood of contractile recovery in a given coronary territory,
or the potential for LV reverse remodelling following revasculariza-
tion. For this purpose, any of the non-invasive imaging techniques
covered may be selected, as long as the limitations of the chosen
technique are recognized in decision making. However, randomized
controlled trials have generally not shown a greater improvement in
either ventricular function or prognosis with coronary revasculari-
zation compared to pharmacological treatment in patients with
heart failure and a reduced LV ejection fraction who have greater
myocardial viability,10,11,149 although extended follow of the STICH
population recently showed modest 16% reduction in mortality
after a median follow-up of 10 years (p ¼ 0.019).150 This may reflect
a failure of previous taxonomies rather than a failure of concept;
further randomized controlled trials are required.
Partial infarction is best appreciated by CMR examination, with
the added benefit that systolic abnormalities not associated with
coronary disease may be explained by characteristic abnormalities
of cardiomyopathy on LGE CMR.
Where infarction and cardiomyopathy co-exist, multi-modality
imaging may be necessary, often including coronary imaging to bet-
ter understand both the dominant aetiology of LVSD and potential
for recovery. Tissue Doppler imaging velocities have been shown to
differ in DCM and ischaemic heart disease, potentially allowing dis-
crimination of causes of LVSD. Late gadolinium enhancement CMR
allows the extent of scarring due to either pathology to be deter-
mined, but not the benefit of any specific therapy.
Mild perfusion defects, with stress defect severity ratios of.45%,
are common in DCM as discussed above. SPECT, PET, or CMR first
pass perfusion in combination with coronary angiography may
facilitate targeted revascularization, if indicated on conventional
grounds, and avoiding unnecessary revascularization.
Conclusion
Consistent adoption of standard nomenclature in clinical practice
will facilitate thinking and hopefully decision making regardless of lo-
cal access to different imaging modalities. Figure 14 summarizes key
imaging findings covered and aims to provide a reference for future
studies. A clear taxonomy for myocardial viability and dysfunction
provides the basis for randomized controlled trials that will provide
the scientific evidence upon which to base clinical decisions.
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